Supplementary Figure S2 : STRING protein network analysis of quisinostat-deregulated genes. This scheme represents the gene product interactions. On the left, the main processes are summarized.
Supplementary Figure S3 : STRING protein network analysis of decitabine-deregulated genes. This scheme represents the gene product interactions. On the left, the main processes are summarized.
Supplementary Tables
Supplementary Table S1 : List of the decitabine-deregulated genes (Benjamini-Hochberg < 0.05, ratio >2). Supplementary Table S2 : List of the quisinostat-deregulated genes (Benjamini-Hochberg < 0.05, ratio >2).
Supplementary Table S3 : Predictive power of the Mu-HA score to predict response to bortezomib of relapsed patients. R=responders (CR + PR + MR). NR = non-responders (NC + PD). PPV = positive predictive value. NPV = negative predictive value. P value was calculated by the Fisher exact test.
Supplementary Table S4 : Cox univariate and multivariate analysis of OS in HM and TT2 patients' cohorts. The prognostic factors were tested as single variable or multi variables using Cox-model. P-values and the hazard ratios (HR) are shown. NS, Not significant at a 5% threshold; GPI, gene expression based proliferation index; ISS, International Staging System; HRS, high-risk score; IFM, Intergroupe Francophone du Myélome; RS, Risk Score. Translocation t(4;14) was predicted in the TT2-corhort as described in material and methods. NA, not available. Supplementary Table S5 : List of gene ontology terms according to DAVID software (Ontology database: GOTERM_BP_FAT) associated with deregulated genes after treatment with quisinostat or decitabine. 
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